Cytek Biosciences, Inc. CTKB
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Total Cash And Short-Term Investments | 255.90M | 262.00M | 262.23M | 261.53M | 261.73M |
| Total Receivables | 60.78M | 51.30M | 56.48M | 72.13M | 61.67M |
| Inventory | 53.47M | 53.11M | 50.38M | 48.66M | 51.91M |
| Prepaid Expenses | 2.91M | 3.25M | 3.84M | 6.90M | 2.85M |
| Finance Division Loans and Leases Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Current Assets | -- | -- | -- | -- | -- |
| Other Current Assets | 5.87M | 8.27M | 6.37M | 2.79M | 10.32M |
| Total Current Assets | 378.94M | 377.93M | 379.30M | 392.00M | 388.49M |
|
|
|||||
| Total Current Assets | 378.94M | 377.93M | 379.30M | 392.00M | 388.49M |
| Net Property, Plant & Equipment | 30.94M | 31.76M | 31.11M | 29.32M | 29.20M |
| Long-term Investments | 16.69M | 16.69M | 16.69M | 16.70M | 16.70M |
| Goodwill | 16.69M | 16.69M | 16.69M | 16.70M | 16.70M |
| Total Other Intangibles | 14.03M | 14.87M | 15.70M | 16.82M | 17.68M |
| Finance Div Loans & Leases LT | -- | -- | -- | -- | -- |
| Total Finance Div Other LT Assets | -- | -- | -- | -- | -- |
| Total Other Assets | 5.55M | 5.69M | 4.71M | 5.10M | 41.25M |
| Total Assets | 446.15M | 446.93M | 449.11M | 461.54M | 494.92M |
|
|
|||||
| Total Accounts Payable | 4.89M | 8.41M | 6.74M | 6.41M | 7.63M |
| Total Accrued Expenses | 29.42M | 25.43M | 21.59M | 25.18M | 21.68M |
| Short-term Debt | 7.75M | 8.83M | 10.11M | 5.70M | 600.00K |
| Current Portion of Long-Term Debt/Capital Leases | -- | -- | -- | -- | -- |
| Finance Division Debt Current | 4.06M | 3.87M | 3.54M | 3.48M | 10.08M |
| Total Finance Division Other Current Liabilities | 38.83M | 37.81M | 38.95M | 37.04M | 35.22M |
| Total Other Current Liabilities | 38.83M | 37.81M | 38.95M | 37.04M | 35.22M |
| Total Current Liabilities | 84.95M | 84.34M | 80.94M | 77.80M | 75.21M |
|
|
|||||
| Total Current Liabilities | 84.95M | 84.34M | 80.94M | 77.80M | 75.21M |
| Long-Term Debt | 99.00K | 246.00K | 386.00K | 525.00K | 655.00K |
| Short-term Debt | 7.75M | 8.83M | 10.11M | 5.70M | 600.00K |
| Capital Leases | 12.78M | 13.52M | 13.44M | 14.04M | 13.49M |
| Finance Division Debt Non Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Non Current Liabilities | -- | -- | -- | -- | -- |
| Total Other Liabilities | 26.96M | 26.88M | 26.71M | 27.43M | 26.99M |
| Total Liabilities | 124.79M | 124.98M | 121.47M | 119.80M | 116.35M |
|
|
|||||
| Common Stock & APIC | 457.57M | 451.98M | 445.88M | 441.24M | 435.41M |
| Retained Earnings | -138.86M | -132.76M | -120.60M | -101.74M | -57.66M |
| Treasury Stock & Other | 2.64M | 2.74M | 2.37M | 2.24M | 821.00K |
| Total Common Equity | 321.35M | 321.95M | 327.64M | 341.74M | 378.57M |
|
|
|||||
| Preferred Stock Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Non Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Convertible | -- | -- | -- | -- | -- |
| Preferred Stock, Others | -- | -- | -- | -- | -- |
| Total Preferred Equity | -- | -- | -- | -- | -- |
|
|
|||||
| Total Common Equity | 321.35M | 321.95M | 327.64M | 341.74M | 378.57M |
| Total Preferred Equity | -- | -- | -- | -- | -- |
| Total Minority Interest | -- | -- | -- | -- | -- |
| Total Equity | 321.35M | 321.95M | 327.64M | 341.74M | 378.57M |
|
|
|||||